Dr Peskin begins by stating, costs are exceedingly consequential. Cancer care and treatment is occupying, and with demographics being what they are, increasingly larger relative total cost of care across the US, including various national organizations.
Dr Peskin begins by stating, “costs are exceedingly consequential. Cancer care and treatment is occupying, and with demographics being what they are, increasingly larger relative total cost of care across the US,” including various national organizations.
He says insurers are working to address cost expenditures across departments as well as with surgical, medical, and radiology oncology partners. They are also including social workers and other care coordinators in that effort.
Some of the other factors payers are looking at include payment models such as bundled payments and areas of supportive care. Additionally, they are considering how to addresses the cost-effectiveness of advanced illness, compassionate care, and how to deal with patients through palliative care appropriately.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
ACA Dependent Coverage Extension and Young Adults’ Substance-Associated ED Visits
September 15th 2025This study examines the impact of the Affordable Care Act (ACA) on substance-associated emergency department (ED) visits among young adults, revealing reduced alcohol-associated visits but unchanged opioid-associated visits.
Read More